| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 4.0 | 2.2 |
| Profit before tax | -15.9 | -17.7 |
| Net income | -15.7 | -16.5 |
| EPS (diluted, $ a share) | $-0.12 | $-0.14 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +78.3% |
|---|---|
| Operating margin | -409.9% |
10-Q filed with the SEC, NASDAQ: OABI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
OmniAb, Inc.: key numbers
- Share price
- $4.89Close, Nov 16
- Market cap
- $713M
- Shares outstanding
- 145.86MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from OmniAb, Inc.
All →OmniAb Earnings Call: Key Takeaways
OmniAb delivered a strong Q3 2026, raising full-year revenue and cash guidance driven by milestone achievements and a major Eli Lilly partnership.
- Call
- Oct 30, 2026, 8:00 AM ET
OmniAb Financial Results
OmniAb reported Q3 2026 financial results, featuring revenue of $4.0 million and a net loss of $15.7 million. The company raised its full-year 2026 revenue guidance to $37-$39 million, citing strong licensing execution and momentum from its xPloration and OmniTides technologies.
“Our strong third-quarter 2026 performance reflects our licensing execution and our focus on driving value for our stakeholders within an efficient business model built on highly differentiated technologies.”
Matt Foehr, Chief Executive Officer of OmniAb
“In addition, the expanded commercial launch of xPloration®, the introduction of OmniTides™, and continued progress across our portfolio of milestone- and royalty-bearing partnered programs reinforce our confidence in the durability of our revenue base and our long-term growth potential. Based on our performance to date and our expectation for the remainder of the year, we are again raising our revenue guidance and cash outlook.”
Matt Foehr, Chief Executive Officer of OmniAb